In diabetes mellitus, increased basal GSK3β activity contributes to accelerated EPC cellular senescence, effect reversed by small molecule antagonism of GSK3β which enhances cell-based therapy following vascular injury [80]. Here, GSK3B is linked to diabetes mellitus.